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ABSTRACT

TRUNCATED MORTALIN IN ANIMAL CANCER
By
Katrina K. Olson
University of New Hampshire, May, 2010
Hematopoetic neoplasia or clam hemocyte cancer (a leukemia-like
disease) has been studied in a number of bivalve molluscs for the last 20 years.
Recent molecular studies of the hemocytes of the soft shell clam, Mya arenaria,
have demonstrated an interaction between p53 and mortalin, the mitochondrial
Hsp70. The former protein is intimately involved in the initiation of cell-cycle
arrest, apoptosis, DNA repair, and cell differentiation. In cancerous clams, wildtype p53 is sequestered in hemocyte cytoplasm by mortalin and cannot be
translocated to the nucleus. This is critical because although p53 is functions
properly, it is unable to enter the nucleus and initiate cell-cycle arrest. This allows
the immortality of cancerous clam hemocytes (CCH). In CCH, wild-type p53 can
be induced to enter the nucleus and trigger apoptosis genotoxically following
treatment with the topoisomerase II inhibitor, etoposide, or non-genotoxically with
the dye, MKT-077. Full-length and truncated (missing exon 3) clam variants of
human mortalin have recently been cloned.

Here I have generated and purified an antibody to the truncated variant of
clam mortalin and have attempted to determine its location within cancerous
clam hemocyte cytoplasm.
I point out problems with the transfection of the truncated mortalin
antibody into clam hemocyte cytoplasm and in localizing antibodies in cancerous
clam hemocytes embedded in water-soluble resins. The results of this study
demonstrate localization of truncated mortalin near mitochondria of cancerous
clam hemocytes.

IX

INTRODUCTION
On the North Eastern coast of the United States, the soft shell clam, Mya
arenaria, develops a fatal blood cancer in > 1 % of virtually all populations
investigated1. This bivalve cancer was first reported in 1977 in clams from
Maine1. The disease has been called a systemic, disseminated neoplasia by the
now defunct Registry of Tumors in Lower Animals (formerly maintained by the
National Cancer Institute), although the most common descriptors in the literature
are hemopoetic, hematopoetic, or hemic neoplasia2. I will use the phrase
cancerous clam hemocytes (CCH) to describe these malignant cells.
Amitotic normal clam hemocytes (NCH) phagocytize bacteria and other
foreign particles from the hemolymph1. CCH undergo continuous mitosis and
lose the ability to phagocytize1. CCH are immortalized cells, constantly replicating
to accumulate in the blood sinuses within the gill, gonad, and digestive gland.
Their increased numbers distort the size and function of these tissues1,
increasing to a point where severe clam hemocyte cancer is fatal for clams3. The
etiology of the disease has not been determined, although both viral agents and
environmental pollutants have been suggested as potentially involved4.
Recently, the cellular mechanisms responsible for clam hemocyte cancer
have been investigated for Mya arenaria

56,7

. In NCH, wild-type p53 is localized

in both the cytoplasm and nucleus, while mortalin is only found in the cytoplasm7.
In CCH, wild-type p53 co-localizes with mortalin in the cytoplasm when the latter
is over-expressed7. P53 binds to the p53-binding domain of mortalin. Mortalin
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retains wild-type p53 in the cytoplasm and, consequently, the transcriptional
functions of p53 in DNA repair and/or apoptosis are negated. In humans, some
patients with glioblastoma and colorectal carcinomas also display sequestration
of wild-type p53 in the cytoplasm, although the mechanism for sequestering p53
is not understood8'9. It is uncertain how the non-transcriptional, mitochondrial
functions of p53 are affected in CCH by p53 sequestration.
Mortalin is the mitochondrial Hsp70 and is a member of the Hsp70 family
of proteins. Mortalin is involved in many different cellular activities including
mitochondrial protein import, intracellular trafficking (e.g. p53), and receptor
internalization10,11.
Both full-length and truncated variants of clam mortalin protein have been
cloned and contain a p53 binding site that is 97% conserved with human
mortalin7,12. While the full-length variant of mortalin is over-expressed in
cancerous clam hemocytes by 1,200-fold, this newly-discovered truncated
variant is over-expressed 620-fold5. The truncated version of mortalin is missing
exon 3, consisting of 90 amino acids from the ATP/ADP binding site, which also
encodes an ATPase. Figure 1 indicates the 90 amino acids (highlighted in red
and representing exon 3) that are missing from truncated mortalin. When p53 is
bound to mortalin, the ATPase is responsible for hydrolysis of ATP to ADP. ATP
binding is required for the association of mortalin with p53, as the ADP-bound
form has a very slow exchange rate. Once mortalin is bound to p53, the
hydrolysis of ATP to ADP allows mortalin to change its conformation and lock in
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p53, with a high binding affinity by closing the binding pocket, and stabilizing the
interaction11.
When Hsp70 proteins are bound to ATP, they cannot act as chaperones
for proteins11. It is uncertain how lacking the ATP/ADP binding domain will affect
the chaperone activities of mortalin. Is the over-expression of truncated mortalin
able to indefinitely bind p53, resulting in the inactivation of p53 in clam hemocyte
cancer or does the loss of the ATPase domain, even with the over-expression of
truncated mortalin, cause truncated mortalin to be unable to interact with p53 5'11.
In this study, I have focused on two main objectives:
Objectivel: To generate and purify an antibody specific for the splice sites of
exons 2 and 4 of truncated clam mortalin.
Objective 2: To use the antibody developed in Objective 1 to localize the
truncated mortalin protein within cancerous clam hemocytes.

Figure 1. Amino acid sequence of full length clam mortalin compared with human
mortalin. The red portion indicates exon 3, the 90 amino acids that are missing
from truncated clam mortalin11.
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CHAPTER 1 - GENERATING AN ANTIBODY FOR TRUNCATED MORTALIN
I.

Objective I: To generate and purify an antibody specific for the splice site
of exons 2 and 4 of truncated clam mortalin.
Hypothesis I: An antibody can be generated for the sequence upstream
and downstream of exon 3 that will identify truncated clam mortalin.

II.

MATERIALS AND METHODS

Peptide Design and Generation
A peptide was designed to the last 7 amino acids in exon 2 (LLPSRLR)
and the first 7 amino acids in exon 4 (METVPYK) of truncated clam mortalin
protein, the 14 amino acids adjacent to the splice site for exon 3. The peptide
consisted of seven amino acids upstream (exon 2), LLPSRLR, and seven amino
acids downstream (exon 4), METVPYK, of the exon splice site (Figure 2). Based
on this amino acid sequence, the peptide, NH2-LLPSRLRMETVPYK-COOH, was
ordered from New England Peptide LLC (Gardner, MA).
BSA Conjugation to the Peptide
In a 1.5 mL microcentrifuge tube, 10mg of Bovine Serum Albumin (BSA)
were dissolved in 500 uL 0.2M sodium phosphate buffer (NaH2P04) (monobasic,
pH 7.5 with 1 M sodium hydroxide (NaOH)). In a second 1.5 mL microcentrifuge
tube, a 30-fold molar excess of the truncated mortalin peptide relative to the BSA
concentration was dissolved in 500 uL of distilled water. The peptide solution was
neutralized by the addition of 1 M NaOH drop-wise until a pH of 7 was reached,
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utilizing pH paper to determine the pH of the peptide soluton. Both the peptide
solution and the BSA solution were combined in a 15 mL Falcon tube.
While being vortexed, 1 mL 20 mM glutaraldehyde was added drop-wise
to the peptide/BSA solution. The peptide/BSA solution was agitated at room
temperature for 30 minutes. Conjugation of the peptide to BSA was terminated
by first adding 250 ul_ of 1 M glycine to the solution, and then agitating the
solution at room temperature for 30 minutes.
The peptide/BSA solution was placed into a 1 cm diameter boiled dialysis
tubing (Spectrum Laboratories, California), and the tubing was sealed shut with a
floating clip. Un-conjugated peptide and BSA were removed by exhaustive
dialysis in 1X phosphate buffered saline (PBS). Exhaustive dialysis, ultrafiltration
of the un-conjugated peptide/BSA, was performed by floating the peptide/BSA
filled tubing in 1 L of 1X PBS (8 g NaCI, 0.2 g KCI, 0.2 g KH 2 P0 4 monobasic, 2.17 g
Na 2 HP0 4 -7H 2 0 dibasic), while stirring at 6°C for 24 hours. After 24 hours, the
tubing was placed into a new solution of 1X PBS and stirred at 6°C for another
72 hours. The dialysate was emptied into a 50 mL Falcon tube and brought to a
final volume of 20 mL with 1X PBS.
Antibody Generation
20 mL of conjugated peptide-BSA were sent to Pacific Immunology Corp
(Ramona, CA). This solution, containing the 14 residue peptide-BSA complex,
was used to immunize two rabbits, labeled 2273 and 2274. A pre-immune bleed
was removed prior to immunization. Bleeds were removed approximately every
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two weeks following initial injection, yielding six bleeds on 10/1/07, 10/15/07,
10/29/07, 11/12/07, 11/19/07, and 11/22/07.
Establishing Relative Antibody Concentrations
A 10 mg/mL solution of BSA was made in 10 ml_ 0.1 M sodium
bicarbonate. Six umoles of the 14 residue peptide were dissolved in 1 mL
distilled water. The peptide solution was neutralized with 1 M NaOH to a pH 7,
diluted in an equal volume of 0.2 M sodium bicarbonate, and chilled on ice, while
Affi-Gel 10 beads (Bio-Rad Laboratories, California) were equilibrated to room
temperature.
A sintered glass funnel (containing a glass mesh) and glass stir rod were
washed sequentially in distilled water, 100% alcohol, and distilled water. The AffiGel 10 was placed into the funnel and stirred with the glass rod. After vacuum
removal of excess liquid, the Affi-Gel was re-suspended in a small volume of 0.1
M sodium bicarbonate. Using a sterile glass rod, the Affi-Gel beads were mixed
and placed in a 50 mL Falcon tube. The volume was adjusted to 50 mL with 0.1
M sodium bicarbonate to make a 50% suspension of the Affi-Gel 10 beads.
The slurry was mixed thoroughly, and 6 mL were poured into a 15 mL
Falcon tube. The peptide solution was added to the slurry in the 15 mL Falcon
tube,

thoroughly

agitated,

and

placed

on

Speci-Mix

Rocker

(Barnstead/Thermolyne, Dubuque, Iowa) overnight at 4°C to allow for adequate
coupling. The BSA solution was treated the same way. The remaining Affi-Gel
solution was combined with the BSA solution in a 50 mL Falcon tube, thoroughly
agitated, and placed on the rocker overnight at 4°C.
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Both Falcon tubes containing Affi-Gel beads were filled with 0.1 M sodium
bicarbonate, and sequentially washed three additional times with the 0.1 M
sodium bicarbonate. Between each wash, the Affi-Gel beads were centrifuged for
1 minute at 10,000 RCF and placed under a vacuum to remove the 0.1 M sodium
bicarbonate. Once the last wash was centrifuged and the sodium bicarbonate
removed, a 1:1 ratio of 0.1 M ethanolamine HCI: Affi-Gel slurry was added to the
Affi-Gel beads and placed on the rocker for 1 hour at room temperature to block
any un-coupled sites on the affi-gel.
Next, the beads were centrifuged for 1 minute at 10,000 RCF and the top
aqueous layer was removed. The beads were washed in 0.1 M sodium
bicarbonate containing 0.5 M sodium chloride (NaCI) followed by 0.1 M sodium
acetate buffer (pH 4 with acetic acid) containing 0.5 M NaCI, and a final wash of
distilled water. After each of these washes, the solution was centrifuged for 1
minute at 10,000 RCF and the upper aqueous layer was removed. This process
of washing the beads, centrifuging, and removing the upper aqueous layer was
repeated with 0.1 M sodium bicarbonate and three times with 1X PBS. Both sets
of beads were stored in 3 M NaCI at 4°C overnight.
The following day, the beads were centrifuged at 10,000 RCF and the
upper aqueous layer was removed. The beads were washed three times with 10
volumes each of 1X PBS, centrifuged at 10,000 RCF, and followed by removal of
the upper aqueous layer. PBS (1X) was added to each tube to create a 1:1 slurry
of peptide beads:1X PBS. In a 1.5 ml_ microcentrifuge tube, 100 uL of the
peptide bead slurry were added to 200 uL of each antibody serum, including the
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pre-immunization serum, and shaken on the rocker for one hour at room
temperature. The bead-antibody solutions were washed five times with 1 mL 1X
NP40

buffer

(140 mM NaCI, 20

mM

tris(hydroxymethyl)aminomethane-

hydrochloric acid (Tris-HCI), 1mM ethylenediaminetetraacetic acid (EDTA), 1%
Tergitol-type NP-40) with the top aqueous layer removed after each wash.
Fifty uL 5X sample buffer (250 mM Tris-HCI pH6.8, 10% SDS, 30%
Glycerol,

0.02%

bromophenol

blue)

were

combined

with

2.5

uL

B-

mercaptoethanol and added to each bead-antibody solution and boiled for three
minutes. Forty uL of each sample buffer/bead-antibody solution was added to the
well of a 4-15% Tris-HCI gel. Ten uL Precision Plus Dual Color Standards (BioRad Laboratories) were added to each of two wells on each gel. The gel was run
in a 1X running buffer of Tris/SDS/glycine (Bio-Rad Laboratories) at 20 mA/gel
for 90 minutes using a Power Pac Basic with Mini Trans Blot (Bio-Rad
Laboratories).
A polyvinylidene fluoride (PVDF) membrane (Bio-Rad Laboratories) was
wetted in 100% methanol for 1 minute, and then both the gel and the membrane
were equilibrated for 5 minutes in transfer buffer (22 mL 2M Tris, 168 mL 2M
Glycine, 350 mL 20% MeOH, 1210 mL de-ionized water). The gel was
transferred onto the PVDF membrane in transfer buffer for two hours at 75V on
ice. The membranes were incubated with anti-rabbit IgG (FC) AD Conjugate
antibodies (Promega, Madison, Wl) at 1:5000 (1 part antibody to 5000 parts 1%
BLOTTO) (blotting-grade blocker, Bio-Rad Laboratories) in 1X Tween/Trisbuffered salt solution (TTBS) (10X TTBS: 2 mL Tween 20, 12.1 g Tris, 17.4 g
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NaCI, 200 ml_ de-ionized water) for 30 minutes at room temperature with
agitation on a Red Rocker Model PR50 (Hoefer Scientific Instruments, San
Francisco, CA). The membranes were washed two times in 5 ml_ 1X TTBS for 15
minutes each. Western blue (Promega Corp, Madison, Wl) was added to each
membrane and agitated until the color developed. The membranes were rinsed
with water and air dried.
Antibody Purification
Two sera from each rabbit, containing the highest relative concentration of
antibody and highest specificity for truncated mortalin, were chosen for
purification. Antibodies from each serum were purified utilizing an identical
apparatus (Figure 2).

Prior to purification, small tubing and stop-cocks were

washed sequentially with water, 95% ethanol, and water. A large ring stand was
equipped with two clamps capable of holding a 3 ml_ syringe. Stop-cocks were
added to the bottom of two 3 ml_ syringes where the needle is typically attached.
A small amount of non-siliconized, glass wool in a loose ball was pushed to the
bottom of the syringe with a transfer pipette (Figure 2).
Syringes in this apparatus were filled with 1X PBS to remove any air
bubbles, and 1X PBS was allowed to pass through until just above the glass
wool. The BSA-beads were added to the top syringe, and the peptide-beads
were added to the bottom syringe (Figure 2). Sera from each of the four bleeds
were purified separately, using two columns for each. 200 ml_ 1X PBS were run
through the eight columns to wash the beads. The columns were stored at 4°C
until use.
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The apparatus was assembled with the columns as described above
(Figure 2), and 200 ml_ 1X PBS were passed through the columns to check for
leaks and to ensure that the beads were hydrated. Fifteen ml_ of the antibody
serum were passed through first the top and then the bottom columns, and the
column void (liquid passing through the bottom column) was collected. The
columns were washed with 10 ml_ 1X PBS. The tubing between the top and
bottom columns was removed from top column. Fifty ml_ 1X PBS were passed
through the bottom column to wash away loosely-associated antibodies. The
peptide column was washed with 20 ml_ 0.5 M NaCI (20 column washes).
Dialysis tubing was boiled, and the remaining NaCI in the column was removed
with a transfer pipette.
Three ml_ 3.5 M magnesium chloride (MgCfe) were added to the column.
The first 5 ml_ 3.5 M MgCI2 voided from each column were collected in clean 15
mL Falcon tubes and labeled Elute 1. A knot was tied in the dialysis bag and the
Elute 1 flow through was added to the dialysis bag, which was closed with a
floating clip. An air bubble was kept in the tubing to ensure the bag would float,
and the bag was placed in 1 L 1X PBS. Another 5 mL 3.5 M MgCb were
collected, labeled Elute 2, and the dialysis process repeated. MgCI2 (4.5 M) was
passed through the column and the first 5 mL and second 5 ml voided and
labeled as Elutes 3 and 4. These were also placed in separate dialysis bags.
The four elutes were placed in 1 L 1X PBS at 4°C overnight with magnetic
stirring. The next day, the 1X PBS was changed for fresh PBS, and the elutes
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were left at 4°C overnight with continued stirring. The four elutes were placed into
separate 15 mL Falcon tubes.
An Ultrospec 2000 (Pharmacia Biotech, Uppsala, Sweden) was used to
determine the concentration of each of the purified antibodies'. At 280 nm, a
reading of 0.1 equaled approximately 0.1 mg/mL of antibody. The purified
antibody solutions were labeled and frozen at -20°C.
Protein Extraction
An NE-PER protein extraction kit (Pierce, Rockford, Illinois) was used to
isolate the cytoplasmic and nuclear protein fractions from CCH. In a
microcentrifuge tube, 1.5 mL of CCH were centrifuged at 2,000 RCF for 10
minutes. This was repeated a second time to increase the amount of CCH
collected, removing the supernatant prior to addition of CCH and after the second
centrifugation. 200 uL ice-cold CER I (from the NE-PER kit) were added to the
CCH and the mixture was vortexed to resuspend the pellet. The tube was
incubated on ice for 10 minutes. Eleven uL CER II (from the NE-PER kit) were
added to the tube, vortexed, and incubated for an additional sixty seconds. The
tube was centrifuged at 18,000 RCF for 5 minutes. The supernatant was placed
in a clean 1.5 mL tube and labeled as the cytoplasmic protein fraction.
The pellet was resuspended in 100 uL ice-cold NER by vortexing, and
incubated on ice for 40 minutes while vortexing the tube every 10 minutes. The
sample was centrifuged at 18,000 RCF for 10 minutes, and the supernatant was
collected. Both the cytoplasmic and nuclear protein fractions were stored at 20°C.
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Antibody Verification
Two hundred uL 5X sample buffer were combined with 10 uL pmercaptoethanol in a 1.5 ml_ tube. Thirty-two uL cytoplasmic CCH protein and 8
uL sample buffer were combined for each antibody sample tested. This protein
solution was denatured in boiling water for three minutes. Ten uL precision plus
dual color protein ladder (Bio-Rad Laboratories) were added to every other well
in a 4-15% Tris-HCI gel. 40 uL of the protein/buffer solution were added to the
remaining five wells. The gel was run for two hours at 20 mA/gel in 1X running
buffer. The resulting gels were transferred to a PVDF membrane overnight at 90
mA at 4°C.
The resulting PVDF membrane was cut to yield one protein sample and
one ladder for each section. Each membrane was placed in 1 % Blotto in 1X
TTBS with a 1:100 dilution of one of the four first elutes of each purified antibody.
The fifth membrane was placed in 1% Blotto in 1X TTBS with a 1:1000 dilution of
MAMOT (Mya arenaria mortalin protein) fraction 2 antibodies, antibodies
previously purified, for a positive control. MAMOT fraction 2 is more concentrated
than the purified truncated mortalin antibodies, allowing for a larger dilution factor
in 1% Blotto. The MAMOT fraction 2 antibody recognizes a region downstream of
the splice site of mortalin, making it possible to identify both truncated and fulllength mortalin. Membranes were agitated for 3 hours at 4°C. Each membrane
was washed two times with 5 ml_ 1X TTBS for 15 minutes each. Western blue
was added to each membrane and agitated until the color developed at which
point the membranes were rinsed with sterile water and air dried.
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Figure 2. Diagrammatic representation of the peptide column used for purification
of each serum. After the serum was run through the two columns, the tubing was
removed from the bottom of the top syringe filled with BSA-beads.
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III.

RESULTS

Establishing Relative Antibody Concentrations
Sera from the seven bleeds from each rabbit (2273 and 2274) and the
pre-immune bleed were evaluated for the highest antibody titer. The bands on
the PVDF membranes were the heavy chain of the antibodies within each serum
from rabbit 2273 (Figure 3) and rabbit 2274 (Figure 4) that was tested. As a
result of heat and detergent treatment, the heavy and light chains had separated.
Once separated, the light chain ran off the gel, leaving the heavy chain to be
visualized by the secondary anti-rabbit antibodies.
Figures 3 and 4 indicate the results of the seven different bleeds from
rabbits 2273 and 2274. Lanes with the most intense staining contained higher
relative antibody concentrations. The pre-immune sera contained no antibodies
that recognized truncated mortalin (Figures 3 and 4). It is possible that the slight
shading observed within the pre-immune sera was unspecific binding of
antibodies to mortalin prior to purification. The bleed from 10/1/07 for rabbit 2273
had the highest relative concentration of antibody against truncated clam mortalin
(Figure 3). The bleed from 10/15/07 for rabbit 2274 had the highest relative
concentration of antibody against truncated clam mortalin (Figure 4). All the other
bleeds, except the pre-immune serum, had similar concentrations of antibodies
against truncated clam mortalin (Figures 3 and 4).
Antibody Purification
Quantification of antibody concentration for the four purified antibody
washes is shown in Table 1. With the exception of 2273 10/1/07, the first elute
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had the highest antibody concentration (Table 1). The fourth elute had the lowest
antibody concentration (Table 1).
Antibody Verification
Immunoblots of the CCH cytoplasmic protein showed proteins at
approximately 28 and 45 kD in lanes 1 and 3 (Figure 5). Lanes 2 and 4 contained
a single protein at approximately 68 kD (Figure 5). Lane 5 contained two proteins
at approximately 68 kD and 74 kD (Figure 5).
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Figure 3. Immunoblot of each serum from rabbit 2273. Lane 1: 11/22/07; Lane 2:
11/15/07; Lane 3: ladder; Lane 4: 11/12/07; Lane 5: 10/29/07; Lane 6: 10/15/07;
Lane 7: ladder; Lane 8: 10/1/07; Lane 9: pre-immune.
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2273
10/1/07
mg/ml
Bute 1
Elute 2
Elute 3
Elute 4

0.09
0.046
0.106
0.021

2273
11/22/07
mg/ml
0.072
0.047
0.065
0.036

2274
10/15/07
mg/ml

2274
11/22/07
mg/ml

0.104
0.053
0.056
0.008

0.106
0.058
0.04
0.032

Table 1. The concentration in mg/ml of antibodies in each purified sera.
Absorbance 280 nm.
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IV.

DISCUSSION
Immunoblotting indicated which of the six bleeds should be purified for

each rabbit. The immunoblot for rabbit 2273 showed that the 10/1/07 serum had
the highest concentration of antibodies out of the six 2273 sera. The 10/15/07
serum had the highest concentration of antibodies out of the six 2274 sera. The
other sera for each rabbit had similar, but lesser concentrations. The pre-immune
serum had no antibodies for truncated clam mortalin.
Based on higher concentrations of antibodies and antibody specificity,
only two sera from each rabbit were purified. The first to be chosen were sera
10/1/07 from 2273 and 10/15/07 from 2274 based on the higher antibody
concentrations. The sera from 11/22/07 of both 2273 and 2274 were also
purified. Although the later sera contained lower concentrations of antibodies,
they should contain antibodies with higher specificity for the peptide resulting
from more precise configurations for the peptide conjugate administered. Time
allows for more precise B cell differentiation towards the antigen, in this case our
peptide, generating high specificity antibodies.
The second immunoblot of the newly purified antibodies showed that
rabbit 2273 had produced antibodies with some specificity for the truncated
mortalin splice site, but not specific enough to recognize truncated mortalin. Two
proteins were recognized by the purified antibodies from rabbit 2273, neither of
which were truncated mortalin. Both purified antibodies from 2274 (10/15/07 and
11/22/07) recognized truncated mortalin only (located at 68 kDa). MAMOT
fraction 2 (an antibody generated for the region downstream of the splice site of
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mortalin), recognized both truncated mortalin, at 68 kDa, and full-length mortalin,
at 74 kDa. These results show that rabbit 2274 11/22/07 first elute antibody is
specific for the truncated clam mortalin and has the highest relative concentration
(Table 1, Figure 5).
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Chapter 2 - LOCALIZATION OF TRUNCATED MORTALIN PROTEIN IN
CANCEROUS CLAM HEMOCYTES (CCH)

Objective II: To use the antibody developed in Objective I to localize truncated
mortalin protein within cancerous clam hemocytes.
Hypothesis II - Truncated mortalin is located near the nuclear pores in cancerous
clam hemocytes.
Hypothesis III - Truncated mortalin antibodies can be transfected into cancerous
clam hemocytes where they will block mortalin from tethering of p53, followed by
apoptosis.
II.

Materials and Methods

Generation of CCH Cytospins
Clams were classified as normal (0% round, non-motile CCH; 100%
attached, motile clam hemocytes), early incipient cancerous (1-50% round, nonmotile CCH), late incipient cancerous (50-99% CCH), or fully cancerous (100%
CCH). CCH were only withdrawn from clams classified as fully cancerous. CCH
were withdrawn from the pericardial sinus of clams with 100% cancerous
hemocytes using a 21 gauge needle attached to a 3 mL syringe. Sea water was
sterile filtered using a .22 urn mesh. A cell suspension of 2.2x106 CCH/mL of sea
water was prepared. 100 uL diluted CCH were placed onto poly-lysine coated
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slides and spun at 133 RCF for eight minutes by a Shandon Cytospin 3 (Thermo
Scientific, Rockford, Illinois) for optimum coverage and spread.
Fixation and Embedding of CCH
Hemolymph, CCH, was removed from the pericardial sinus of clams and
centrifuged at 14,000 RCF for 15 seconds with a Beckman Coulter Microfuge
22R Centrifuge (Fullerton, CA). The supernatant was removed and 1 ml_ 2.5%
glutaraldehyde in filtered sea water was added to the tube. The solution was
vortexed until the pellet floated and placed on a Glas Col mini-rotator (Terre
Haute, IN) at 35 rpm for 1 hour. The tube was centrifuged again. The supernatant
was removed, and 1ml of distilled water was added. The solution was vortexed
until the pellet floated and placed on a mini-rotator at 35 rpm for 10 minutes. The
tube was centrifuged again and the supernatant removed.
The pellet was dehydrated in increasing concentrations of ethanol (20%,
50%, 70%, 95%, and 100%), rotated at 35 rpm for 10 minutes, centrifuged at
14,000 RCF for 15 seconds, and the supernatant removed. The pellet in 100%
ethanol was centrifuged at 10,000 RCF for 30 seconds. The supernatant was
removed and 500 uL of a 1:1 solution of 100% ethanol to Pelco Acrylate Resin
(Ted Pella Inc., Redding, CA) were added to the pellet.
The pellet was left at room temperature for 1 hour and agitated every 15
minutes with a transfer pipette. The solution was centrifuged at 10,000 RCF for
30 seconds and the supernatant was removed. 250 uL Pelco Acrylate Resin
were added to the pellet and incubated for 1 hour, agitating every 15 minutes
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with a transfer pipette. The solution was centrifuged and the supernatant
removed. This process was performed twice to remove any ethanol residue.
Finally, 250 uL Pelco Acrylate Resin were added to the pellet. The pellet
and acrylate resin were placed into a gelatin capsule (EMS, Hatfield, PA),
centrifuged at 10,000 RCF for 30 seconds, and allowed to polymerize for
approximately 12 hours at 60°C. The gelatin capsule was filled to the top with the
acrylate resin and incubated at 60°C for 12 hours. Five um sections were cut
using a Reichert OMU3 ultramicrotome with glass knives and heated in a drop of
water on poly-lysine coated slides until dry.
Localization of Truncated Mortalin within CCH Embedded in Plastic and as
Cytospins
Sections of CCH on poly-lysine coated slides were placed in a Coplin jar
containing de-ionized water for 10 minutes to start the hydration process of the
CCH sections. Cytospins of CCH prepared as described above were fixed and
permeabilized in cold acetone for 10 minutes. Both sets of slides were placed in
a Coplin jar with 0.3% H2O2 in methanol to initiate permeabilization of the CCH
sections and rocked for 30 minutes on a Red Rocker Model PR50 (Hoefer
Scientific Instruments, San Francisco, CA). The slides were rocked in Vectastain
buffer (1.2 g mono-basic NaP0 4 , 9 g NaCI, 1 ml Trition X-100, and final volume 1
liter with de-ionized water) for 10 minutes.
A Vectastain ABC kit for rabbit IgG and a DAB substrate kit, 3,3'diaminobenzidine (Vector laboratories Inc, Burlingame, CA) provided the normal
serum, secondary-antibody, ABC solutions, DAB, and DAB enhancer. In the end,
the two kits combined attach a substrate to the IgG antibody and allow
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visualization via a colorimetric reaction. The slides were incubated with dilute
normal serum (3 ml_ Vectastain buffer and 1 drop of concentrated normal serum
from kit) in a hydration chamber for 20 minutes. The hydration chamber
consisted of a Petri dish with a wet thin sponge on the bottom, two thin, round
plastic tubes at either end of the dish (upon which slides rested), and a second
Petri dish as a lid. Both Petri dishes were covered with tin-foil on the outside to
protect the slides from light during incubation.
The slides were incubated overnight (24 hours) in the hydration chamber
with 50 uL of a 1:4 solution of the clam polyclonal antibody MAMOT fraction 2
(specific for both truncated and full-length mortalin) or 2274 11/22/07 elute 1
(specific for truncated mortalin): dilute normal serum. A negative control slide
with sections of CCH was incubated with 50 ul dilute normal serum. The following
day, another 50 ul of 1:4 solution of antibody:dilute normal serum or just dilute
normal serum (negative control) was added to the CCH slides in the hydration
chamber and incubated for a second night in the chamber for maximum delivery
into the CCH. The CCH cytospin slides were continued to the 10 minute
Vectastain buffer step below.
The CCH slides were incubated in Vectastain buffer for 30 minutes, while
the CCH cytospin slides were incubated in Vectastain buffer for 10 minutes. The
embedded CCH slides were incubated overnight while the CCH cytospin slides
were incubated for 1 hour in the hydration chamber in secondary goat anti-rabbit
antibody solution (2.5 ml of vectastain buffer, 1 drop of dilute normal serum from
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kit, and 1 drop of concentrated secondary antibody from kit, a biotin-labeled goat
antibody to rabbit IgG heavy chain).
The following day for embedded CCH slides (or an hour after having
incubated in the secondary antibody solution for CCH cytopsins), the slides were
rocked in Vectastain buffer for 10 minutes. The ABC solution contained avidin,
which binds multiple sites on biotin at the site of the primary antibody/protein of
interest and was made 30 minutes prior to use (2.5 ml_ of vectastain buffer, 1
drop of A from kit, Avidin DH solution, and 1 drop of B from kit, biotinylated
enzyme). The slides were incubated with the ABC solution for 30 minutes in the
hydration chamber. The slides were rocked in Vectastain buffer for 10 minutes to
remove excess ABC solution while maintaining permeability of the CCH sections.
The DAB Substrate Kit 3,3'-diaminobenzidine was used to react with the
avidin substrate previously attached to the slides from the ABC solution. The
slides were incubated in the hydration chamber with 400 uL DAB (2.5 ml_ water,
1 drop buffer from kit, 2 drops DAB from kit, and 1 drop H 2 0 2 from kit) until a tan
color developed, about 60-90 minutes depending on color development. The
slides were rinsed in water and placed in 0.05 M sodium bicarbonate, pH 9.6, for
10 minutes. The slides were incubated with DAB Enhancing Solution (Vector
Laboratories Inc, Burlingame, CA) for 20 seconds. The DAB Enhancing Solution
enhances the reaction product from DAB to increase the sensitivity of the kit.
The CCH slides were rinsed in de-ionized water and air dried. The CCH
cytospin slides were dehydrated for 1 minute each in an increasing ethanol
series followed by xylene (50%, 70%, 95%, and 100% ethanol). The slides were
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removed from xylene and immediately mounted under a 2x2 cm coverslip using
Permount (Fisher Scientific). The slides were examined at 63X bright field (BF)
on a Zeiss Axioplan II MOT equipped with epifluorescence, an AxioCam MR
camera, and AxioVision 4.3 software (Carl Zeiss, Inc., Thornwood, NJ).
Transfection of Antibodies into CCH using Chariot
MAMOT fraction 2 (positive control), rabbit 2274 11/22/07 elute 1, and
cytochrome C antibodies were each transfected into a set of CCH. For each set,
and for a negative control, 2 uL of Chariot Protein Delivery Reagent (Active Motif,
Carlsbad, CA) were combined with 50 uL of nuclease-free water. Chariot delivers
antibodies into live cells by one of two possible ways: 1) by creating a pore in the
cell membrane which allows the antibody to flow into the cell or 2) by attaching to
the antibody on the outside of the cell and flipping it to the inside of the cell. Of
the two methods, the one responsible for transfection has not been verified.
Because there were four different treatments (3 antibodies, MAMOT, rabbit 2274,
and cytochrome C, and a negative control), 8 uL of Chariot were added to 200 uL
of nuclease-free water (Chariot Protein Delivery Reagent kit).
1.5 ug antibody (MAMOT fraction 3, rabbit 2274 11/22/07 elute 1, or
cytochrome C rabbit polyclonal IgG antibody (Santa Cruz Biotechnology, Santa
Cruz, CA) were brought to a final volume of 50 ul_ with 1X PBS. The 50 uL
antibody solution was combined with 52 uL of the Chariot-water solution. For the
negative control, 52 uL of the Chariot-water solution were combined with 50 uL
1X PBS. The antibody-Chariot solution was incubated at room temperature for 30
minutes.
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1.5 mL of CCH were removed from the pericardial sinus of a 100%
cancerous clam as described above and placed in a microcentrifuge tube on ice.
The concentration of CCH was determined using a hemocytometer. CCH
(0.1x106 cells) were added to each of the three chariot-antibody solutions as well
as to the negative control. The volume was brought to 150 uL with filtered sea
water. The four solutions containing CCH were incubated at 4°C for 90 minutes.
A first set of cytospins was created for each cell solution with 72 uL of the cell
solution per slide. The cytospins were spun at 133 RCF for 8 minutes. The
remainder of each CCH solution was left to incubate for an additional 90 minutes
at 4°C. A second set of cytospins was spun at 133 RCF for 8 minutes with 72 uL
of the cell solution.
Localization of Truncated Mortalin within Chariot-Treated CCH
Chariot-treated CCH cytospins were incubated in cold acetone for 10
minutes. The slides were rinsed with Vectastain buffer and placed in 0.3% H2O2
in methanol for 30 minutes. The slides were incubated in Vectastain buffer for 10
minutes followed by incubation in the hydration chamber with dilute normal
serum for 20 minutes.
To detect truncated

mortalin antibody,

chariot-treated

CCH were

incubated in the hydration chamber with secondary antibody solution for 1 hour.
Preparation of these slides was as in the above section Localization of Truncated
Mortalin within CCH as Cytospins. The slides were examined at 63X bright field
(BF) on a Zeiss Axioplan II MOT equipped with epifluorescence, an AxioCam MR
camera, and AxioVision 4.3 software.
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III.

RESULTS

Localization of Truncated Mortalin within CCH Embedded in Plastic
These

preparations were

used to determine whether

perinuclear

localization of clam mortalin was attributable to full length, to truncated mortalin,
or to both7'12. Neither the truncated nor the full-length antibody detected any
variant of mortalin within the CCH embedded in plastic (Figure 6).
Localization of Truncated Mortalin in CCH cytospins
Results depended on which primary antibody was initially transfected into
CCH. Full length clam mortalin antibody (MAMOT), which recognizes both full
length and truncated variants of clam mortalin, indicated that clam mortalin was
evenly distributed in the cytoplasm (Figure 7-1). Truncated clam mortalin was
restricted to small spots within the cytoplasm and not in the nuclei of CCH
(Figure 7-2). Truncated clam mortalin was not detected in control CCH (Figure 73).
Localization of Truncated Mortalin within Chariot-Treated CCH
When CCH were treated with MAMOT (Figure 8-1), truncated mortalin antibody
(Figure 8-2), and cytochrome C (Figure 8-3) similar distributions of protein were
observed in cytoplasm. None of these proteins was detected in control CCH
(Figure 8-4). Following all three treatments, the structure of CCH differed from
that of untreated CCH. The plasma membranes of CCH, independent of
treatment, were ruffled (Figure 8-1 to 8-3).
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Figure 6. CCH embedded within Pelco Acrylate Resin: 1) clam full-length
mortalin antibody (MAMOT) (fraction 2) and 2) control; N = nucleus; Scale bars =
10 urn.
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truncated mortalin antibody (2274 11/22/07 elute 1) and 3) control; N = nucleus;
Scale bars = 10 um.
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Figure 8. CCH transfected with: 1) MAMOT (fraction 2), 2) clam truncated
mortalin antibody (2274 11/22/07 elute 1), 3) cytochrome C antibody and 4)
control; N = nucleus; Scale bars = 10 urn.
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IV.

DISCUSSION

Localization of Truncated Mortalin within CCH Embedded in Plastic
In CCH embedded in Pelco Acrylate Resin, there was no evidence that
proteins had been localized using MAMOT (full-length and truncated mortalin)
antibodies (Figure 6). Truncated and full-length mortalin proteins are both found
in high concentration within CCH as demonstrated by results from western
blotting7. CCH treated with full-length antibody (MAMOT fraction 2) should have
identified both of these proteins as indicated in Walker et al., 2006 and did not do
so in these preparations. This suggests that the antibodies we used did not
penetrate the hydrophilic acrylate resin.
Localization of Truncated Mortalin within CCH as Cytospins
Control CCH that were not incubated with either primary antibody did not
stain (Figure 7-3). Localization of clam full-length and truncated mortalin within
CCH is illustrated in Figures 7-1 and 7-2 respectively. Their cytoplasmic
localization within CCH is unique. Clam full-length mortalin is evenly distributed in
the cytoplasm (Figure 7-1). Clam truncated mortalin is localized to small spots at
discrete locations in the cytoplasm (Figure 7-2). While some of these spots
surround the nucleus, it is likely that truncated mortalin is associated with
mitochondria, which have similar cytoplasmic distribution near the nucleus and
also throughout the cytoplasm. In humans, mortalin is transported to and
ultimately located in the mitochondrial matrix. My results seem to refute
Hypothesis II which proposed that truncated mortalin would be localized
exclusively around the nuclear pores.
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Localization of Truncated Mortalin within Chariot Treated CCH
Control CCH that were not incubated with antibody did not stain (figure 84). Figures 8-1 through 8-3 demonstrated a generalized darkening of all cellular
components following transfection with all three antibodies (truncated and fulllength mortalin antibody and cytochrome C) in Chariot treated CCH. Such
darkening is often observed under the conditions outlined in this study and is
interpreted here as a failure to successfully transfect CCH in all cases. These
results indicate that transfection with the Chariot system under the conditions
outlined in the Materials and Methods above did not deliver truncated mortalin
antibodies into CCH.
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CONCLUSIONS AND FUTURE DIRECTIONS
Previous research indicates that mortalin is co-sequestered with p53 near
the centriole or microtubular array in the cytoplasm of CCH, but not NCH7. The
same study demonstrated that competitive inhibition of mortalin by the cationic
inhibitor MKT-077 promoted access of wild-type p53 to the nucleus and in some
cells induced apoptosis5'7. Genotoxic-stress to CCH, resulting from etoposide
treatment, increases the levels of p53 mRNA as shown by QPCR and suggests
that increased levels of p53 can lead to apoptosis5.
Recently a splice variant of full-length clam mortalin, missing exon 3 was
cloned12. My study was designed to develop an antibody that could differentiate
truncated from full-length clam mortalin and to demonstrate the localization of
truncated mortalin within the cytoplasm of CCH using the newly designed
antibody. Based on the results in Walker et al., 2006, I hypothesized that
truncated mortalin would be localized exclusively near or surrounding the nuclear
pores in CCH. The results of this study demonstrate that truncated mortalin was
localized at both the centrioles and the mitochondria as well as near the nucleus,
although not uniformly localized near the nuclear pores as was hypothesized.
Mortalin is a member of the Hsp-70 family of proteins that has been
localized at multiple sites in transformed human cell lines. Although it is unclear
how mortalin is delivered in different cell lines, multiple subcellular sites have
been identified including, mitochondria, endoplasmic reticulum, cytoplasmic
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vesicles, and cytosol15,16,17,18,19'20'21. The principle site for mortalin's function is
mitochondria11'15'17'18'21.
In an earlier study of CCH, mortalin was localized both perinuclearly and
at mitochondria, respectively. The perinuclear localization of mortalin was
documented in Walker et al (2006) where mortalin and p53 were co-localized
near the nucleus in CCH, both in vivo and in vitro7. In the current study of CCH, it
appears that truncated mortalin is localized both in the perinuclear regions of the
CcH and at mitochondria, although this needs to be tested in conjunction with
FITC labeled WGA and cytochrome C antibodies respectively.
The transfection of antibodies into CCH using Chariot resulted in the
darkening of all cellular components. All attempts at transfecting antibodies used
in this study using Chariot methodology indicated that more studies need to be
carried out to successfully transfect antibodies into CCH.
Walker et al (2006) demonstrated the co-localization of p53 and mortalin
within CCH but not NCH7. When this paper was published, the truncated variant
of mortalin had not been detected.
Although the current study indicates that truncated mortalin is confined to
two main locations within CCH, perinuclear and mitochondrial, its role in p53
sequestration has not been resolved. Since previous studies indicated p53 at
perinuclear localization, it is possible that truncated mortalin will be found colocalized with p53 in subsequent studies at perinuclear locations. If truncated
mortalin is associated with mitochondria and with the nucleus, it is possible that it
could be involved in both genotoxic and non-genotoxic stress related induction of
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p53 when cytoplasmic sequestration of wild-type p53 is defeated in CCH. Both of
these possibilities are dependent on the idea that truncated mortalin is able to
associate with p53 despite the lack of the ATPase domain in the non-existent
exon 3.
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